These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11425622)

  • 21. Huntington's disease. Exploiting expression.
    Bates GP
    Nature; 2001 Oct; 413(6857):691, 693-4. PubMed ID: 11607014
    [No Abstract]   [Full Text] [Related]  

  • 22. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH; Li XJ
    Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders.
    Wang Y; Meriin AB; Costello CE; Sherman MY
    Prion; 2007; 1(2):128-35. PubMed ID: 19164926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyglutamine neurodegeneration: minding your Ps and Qs.
    Paulson H
    Nat Med; 2003 Jul; 9(7):825-6. PubMed ID: 12835695
    [No Abstract]   [Full Text] [Related]  

  • 25. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.
    Benn CL; Sun T; Sadri-Vakili G; McFarland KN; DiRocco DP; Yohrling GJ; Clark TW; Bouzou B; Cha JH
    J Neurosci; 2008 Oct; 28(42):10720-33. PubMed ID: 18923047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. General transcriptional repression by polyglutamine disease proteins is not directly linked to the presence of inclusion bodies.
    Hoshino M; Tagawa K; Okuda T; Okazawa H
    Biochem Biophys Res Commun; 2004 Jan; 313(1):110-6. PubMed ID: 14672705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Huntington's disease--making connections.
    Greenamyre JT
    N Engl J Med; 2007 Feb; 356(5):518-20. PubMed ID: 17267914
    [No Abstract]   [Full Text] [Related]  

  • 28. Qs in the nucleus.
    Orr HT
    Neuron; 2001 Sep; 31(6):875-6. PubMed ID: 11580886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
    Bao J; Sharp AH; Wagster MV; Becher M; Schilling G; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5037-42. PubMed ID: 8643525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
    Ghosh S; Feany MB
    Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurodegenerative disease: neuron protection agency.
    Orr HT
    Nature; 2004 Oct; 431(7010):747-8. PubMed ID: 15483586
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.
    Diamond MI; Robinson MR; Yamamoto KR
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):657-61. PubMed ID: 10639135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical aggregation versus oligomerisation properties of mutant and wild-type huntingtin fragments.
    Rubinsztein DC; Huntington JA
    Exp Neurol; 2006 Jun; 199(2):243-4. PubMed ID: 16631742
    [No Abstract]   [Full Text] [Related]  

  • 34. Huntington's disease: the challenge for cell biologists.
    Tobin AJ; Signer ER
    Trends Cell Biol; 2000 Dec; 10(12):531-6. PubMed ID: 11121745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models.
    Tauffenberger A; Chitramuthu BP; Bateman A; Bennett HP; Parker JA
    Hum Mol Genet; 2013 Feb; 22(4):782-94. PubMed ID: 23172908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward cell specificity in SCA1.
    Humbert S; Saudou F
    Neuron; 2002 May; 34(5):669-70. PubMed ID: 12062012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
    Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
    Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inefficient degradation of truncated polyglutamine proteins by the proteasome.
    Holmberg CI; Staniszewski KE; Mensah KN; Matouschek A; Morimoto RI
    EMBO J; 2004 Oct; 23(21):4307-18. PubMed ID: 15470501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
    Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversing neurodegeneration: a promise unfolds.
    Orr HT; Zoghbi HY
    Cell; 2000 Mar; 101(1):1-4. PubMed ID: 10778849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.